Brain cancer vaccine succeeds at prolonging survival in Phase 3 trial
A Phase 3 trial for Northwest Biotherapeutics’s DCVax-L vaccine extended survival in patients with gliobastoma for many months, or in some cases, years: according to new data.
Continue Reading https://www.biopharma-reporter.com
Join the Discussion